Get the Stockscreener App
39.15
0.20%
0.08
After Hours:
39.30
0.15
+0.38%
Exelixis Inc stock is traded at $39.15, with a volume of 2.47M.
It is up +0.20% in the last 24 hours and up +3.16% over the past month.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$39.07
Open:
$38.73
24h Volume:
2.47M
Relative Volume:
0.77
Market Cap:
$10.54B
Revenue:
$2.17B
Net Income/Loss:
$521.27M
P/E Ratio:
22.12
EPS:
1.77
Net Cash Flow:
$633.79M
1W Performance:
+3.35%
1M Performance:
+3.16%
6M Performance:
+5.24%
1Y Performance:
+48.80%
1-Day Range:
$38.59
$39.27
1-Week Range:
$36.78
$39.27
52-Week Range:
$25.17
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
39.15 | 10.15B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-24-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-24-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Exelixis Announces New Executive VP for R&D - MSN
market reaction to exelixis inc.’s recent newsMarket Performance Report & Weekly Breakout Opportunity Watchlist - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc.EXEL - FinancialContent
Exelixis at H.C. Wainwright: Strategic Growth and Innovation - Investing.com
Transcript : Exelixis, Inc. Presents at H.C. Wainwright 27th Annual Global Investment Conference, Sep-10-2025 08 - MarketScreener
Kestra Investment Management LLC Has $744,000 Position in Exelixis, Inc. $EXEL - MarketBeat
AlphaQuest LLC Sells 14,154 Shares of Exelixis, Inc. $EXEL - MarketBeat
New Vernon Capital Holdings II LLC Takes $8.31 Million Position in Exelixis, Inc. $EXEL - MarketBeat
NFJ Investment Group LLC Raises Holdings in Exelixis, Inc. $EXEL - MarketBeat
Exelixis at Morgan Stanley Conference: Oncology Growth and Strategic Focus - Investing.com
Exelixis, Inc. $EXEL Shares Purchased by Royal Bank of Canada - MarketBeat
Moving Average Crossover Confirms Uptrend in Exelixis Inc.2025 Growth vs Value & Low Drawdown Investment Strategies - beatles.ru
Here's Why Exelixis (EXEL) is a Strong Momentum Stock - Yahoo Finance
Exelixis Inc. Recovery Likely Here’s What Data ShowsWeekly Trading Summary & Free Real-Time Volume Trigger Notifications - beatles.ru
Will Exelixis Inc. Hold Gains Into CloseMarket Growth Review & Daily Growth Stock Investment Tips - beatles.ru
Jacobs Levy Equity Management Inc. Sells 90,427 Shares of Exelixis, Inc. $EXEL - MarketBeat
What’s Exelixis Inc.’s historical return2025 Volatility Report & Stock Timing and Entry Methods - beatles.ru
Exelixis Gains Analyst Confidence as Cancer Studies Advances - MSN
Exelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&D - MSN
Analyzing Exelixis Inc. with risk reward ratio chartsRisk Management & Precise Buy Zone Tips - Newser
Is Exelixis Inc. building a consolidation baseWeekly Trend Report & Smart Swing Trading Alerts - Newser
Will Exelixis Inc. be affected by tariffs2025 Stock Rankings & Real-Time Market Sentiment Reports - خودرو بانک
Can Exelixis Inc. lead its sector in growth2025 Institutional Moves & AI Optimized Trading Strategy Guides - خودرو بانک
What drives Exelixis Inc.’s stock priceSwing Trade & Growth Focused Stock Pick Reports - خودرو بانک
Trexquant Investment LP Cuts Stock Holdings in Exelixis, Inc. $EXEL - MarketBeat
Exelixis, Inc. (EXEL): A Bull Case Theory - MSN
Can Exelixis Inc. be recession proofDividend Hike & Daily Growth Stock Investment Tips - خودرو بانک
Exelixis, Inc. (EXEL): A High-Conviction Biotech Play with Cash-Generative Momentum and a De-Risked Pipeline - AInvest
Using data models to predict Exelixis Inc. stock movementEarnings Miss & Weekly Watchlist of Top Performers - Newser
Ranking Exelixis Inc. among high performing stocks via tools2025 Trade Ideas & Weekly Hot Stock Watchlists - Newser
Is Exelixis Inc.’s growth already priced inJuly 2025 Snapshot & Weekly Top Gainers Trade List - خودرو بانک
What candlestick patterns are forming on Exelixis Inc.Market Growth Report & Risk Managed Investment Entry Signals - Newser
Price momentum metrics for Exelixis Inc. explained2025 Support & Resistance & Long-Term Safe Return Strategies - Newser
Live market analysis of Exelixis Inc.2025 Analyst Calls & Growth Focused Entry Reports - Newser
Will Exelixis Inc. benefit from AI trendsRecession Risk & Precise Trade Entry Recommendations - خودرو بانک
Merck KGaA finds its next R&D leader; Exelixis retools management team as medical chief leaves - Endpoints News
Institutional scanner results for Exelixis Inc.Weekly Stock Analysis & Short-Term Trading Alerts - Newser
Will Breakout in Exelixis Inc. Sustain Through Next WeekMarket Performance Report & Low Risk Entry Point Guides - 더경남뉴스
Is Exelixis Inc. backed by strong institutional buyingJuly 2025 Review & Safe Capital Growth Tips - خودرو بانک
Statistical indicators supporting Exelixis Inc.’s strengthWeekly Profit Summary & Daily Risk Controlled Trade Plans - Newser
Intraday pattern recognizer results for Exelixis Inc.2025 Institutional Moves & Safe Swing Trade Setup Alerts - Newser
Exelixis Cuts 130 Jobs as Company Shuts Down Pennsylvania Facility - AInvest
Exelixis Investigated for Misleading Statements, Shares Fall 16.8% - AInvest
Exelixis shuttering Pennsylvania site, laying off 130 employees - Seeking Alpha
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm - WV News
Exelixis’ Strategic Momentum in Oncology Innovation - AInvest
Exelixis at Citi’s Biopharma Conference: Strategic Growth and Innovation - Investing.com
Is Exelixis Inc. stock bottoming outPortfolio Update Summary & Low Risk High Reward Trade Ideas - Newser
Exelixis at Wells Fargo Conference: Strategic Growth and Innovation - Investing.com
Transcript : Exelixis, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 03 - MarketScreener
Exelixis (EXEL): Leveraging ZANZA's Breakthrough and Strong Cash Flow for Long-Term Value Creation - AInvest
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):